Advances in urologic oncology "OncoForum": The best of 2019.
CONCLUSIONS: These data show the implementation of immunotherapy as a novel alternative against renal and bladder cancer. The arrival of new agents for advanced urothelial carcinoma should be highlighted, and the efficacy of enzalutamide and apalutamide in de novo metastatic prostate cancer is established. In metastatic CRPC, cabazitaxel and olaparib (targeting mutations) are promising therapeutic options.
PMID: 32948345 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Gómez-Veiga F, Alcaraz Asensio A, Burgos Revilla J, Cózar Olmo J Tags: Actas Urol Esp Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Gastroschisis Repair | Genetics | Immunotherapy | Kidney Cancer | Politics | Prostate Cancer | Science | Toxicology | Urology & Nephrology | Yervoy